FDA OKs Mesenchymal Stromal Cell Therapy for GVHD
The US Food and Drug Administration (FDA) has approved remestemcel-L (Ryoncil, Mesoblast Ltd), an allogeneic bone marrow‒derived mesenchymal stromal cell (MSC) therapy for steroid-refractory acute graft-vs-host disease (SR-aGVHD) in children 2 months of age or older. It’s the first MSC product approved by the FDA for any indication…
The US Food and Drug Administration (FDA) has approved remestemcel-L (Ryoncil, Mesoblast Ltd), an allogeneic bone marrow‒derived mesenchymal stromal cell (MSC) therapy for steroid-refractory acute graft-vs-host disease (SR-aGVHD) in children 2 months of age or older. It’s the first MSC product approved by the FDA for any indication…
Read More
About Author
